CIM
PRCT icon

Contravisory Investment Management’s Procept Biorobotics PRCT Stock Holding History

Contravisory Investment Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,092
Closed -$410K – 435
2024
Q4 		$410K Sell
5,092
-3
-0.1% -$256 0.09% 170
2024
Q3 		$408K Hold
5,095
– – 0.09% 162
2024
Q2 		$311K Buy
+5,095
New +$303K 0.07% 168

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Contravisory Investment Management's PRCT Position: Q1 2025 in Review

Contravisory Investment Management sold out of Procept Biorobotics (PRCT) in Q1 2025, closing a stake of 5,092 shares — an estimated $410K sold.

Contravisory Investment Management first reported a position in PRCT in Q2 2024 and held it in 3 quarters. The position peaked at $410K in Q4 2024. 279 funds tracked by Wall St. Rank hold PRCT as of Q1 2025.

  • Contravisory Investment Management reported no remaining Procept Biorobotics position as of Q1 2025 after selling out during the quarter.
  • Contravisory Investment Management sold 5,092 Procept Biorobotics shares in Q1 2025, an estimated $410K.
  • Contravisory Investment Management first reported a position in Procept Biorobotics in Q2 2024 and held it in 3 quarters.
  • Contravisory Investment Management's Procept Biorobotics position peaked at $410K in Q4 2024.
  • 279 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2025.

Based on Contravisory Investment Management's 13F filing for Q1 2025, filed 10 Apr 2025.